Carbon monoxide and iron modulate plasmatic coagulation in Alzheimer's disease

Current Neurovascular Research

Volumn 12, Issue 1, 2015, Pages 31-39

  Nielsen, Vance G ^a   Pretorius, Etheresia ^b   Bester, Janette ^b   Jacobsen, Wayne K ^a   Boyle, Patrick K ^a   Reinhard, Joao P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Alzheimer's disease; Carbon monoxide; Heme oxygenase; Iron; Scanning electron microscopy; Thrombelastography

Indexed keywords

CARBON MONOXIDE; FERRITIN; FIBRIN; HEME OXYGENASE; IRON; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOGEN; THROMBIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; MALE; PLASMA; PRIORITY JOURNAL; THROMBUS; VISCOELASTICITY; BLOOD; BLOOD CLOTTING; COHORT ANALYSIS; DRUG EFFECTS; METABOLISM; MIDDLE AGED; SCANNING ELECTRON MICROSCOPY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOOD COAGULATION; CARBON MONOXIDE; COHORT STUDIES; FEMALE; FERRITINS; FIBRINOGEN; HUMANS; IRON; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PLASMA; THROMBIN;

EID: 84926378068     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202612666150102150042     Document Type: Article

References (34)

1. Armstrong RA. A critical analysis of the 'amyloid cascade hypothesis'. Folia Neuropathol 2014; 52 (3): 211-5.
2. Karim S, Mirza Z, Kamal MA, et al. The role of viruses in neurodegenerative and neurobehavioral diseases. CNS Neurol Disord Drug Targets 2014; 13 (7): 1213-23.
3. Stone J, Johnstone DM, Mitrofanis J, O'Rourke M. The mechanical cause of age-related dementia (Alheimer's Disease): the brain is destroyed by the pulse. J Alzheimers Dis 2014, in press, PMID: 25318547.
4. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza J. Homeostasis of metals in the progression of Alzheimer's disease. Biometals 2014; 27 (3): 539-49.
5. Crespo AC, Silva B, Marques L, et al. Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic homeostasis dysregulation. Neurobiol Aging 2014; 35 (4): 777-85.
6. Mitra J, Guerrero EN, Hegde PM, et al. New perspectives on oxidized genome damage and repair inhibition by pro-oxidant metals in neurological diseases. Biomolecules 2014; 4 (3): 678-703.
7. Braidy N, Poljak A, Marjo C, et al. Metal and complementary molecular bioimaging in Alzheimer's disease. Front Aging Neurosci 2014; 6: 138.
8. Grunblatt E, Bartl J, Riederer P. The link between iron, metabolic syndrome, and Alzheimer's disease. J Neural Transm 2011; 118 (3): 371-9.
9. Letra L, Santana I, Seica R. Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines. Metab Brain Dis 2014; 29 (3): 563-8.
10. Rios JA, Cisternas P, Arrese M, Barja S, Inestrosa NC. Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol 2014; 121C: 125-46.
11. Purandare N, Burns A, Daly KJ, et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: casecontrol study. BMJ 2006; 332 (7550): 1119-24.
12. Purandare N, Voshaar RC, Morris J, et al. Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia. Biol Psychiatry 2007; 62 (4): 339-44.
13. Gupta A, Watkins A, Thomas P, et al. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. Int J Clin Pract 2005; 59 (1): 52-7.
14. Xu G, Zhang H, Zhang S, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 2007; 62 (7): 1070-5.
15. Lipinski B, Pretorius E. The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium. Front Hum Neurosci 2013; 7: 735.
16. Bester J, Buys AV, Lipinski B, Kell DB, Pretorius E. High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease. Front Aging Neurosci . 2013; 5: 88.
17. Nielsen VG, Pretorius E. Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood Coagul Fibrinolysis 2014; 25 (7): 695-702.
18. Barone E, Di Domenico F, Mancuso C, Butterfield DA. The Janus face of the heme oxygenase/biliverdin reductase system in Alzhiemer disease: It's time for reconciliation. Neurobiol Dis 2014; 62: 144-59.
19. Barone E, Di Domenico F, Sultana R, et al. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzhiemer disease and mild cognitive impairment. Free Radic Biol Med 2012; 52 (11-12): 2292-301.
20. Di Domenico F, Barone E, Mancuso C, et al. HO-1/BVR-A system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease. J Alzheimers Dis 2012; 32 (2): 277-89.
21. Song W, Zukor H, Liberman A, et al. Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. Exp Neurol 2014; 254: 78-89.
22. Leffler CW, Parfenova H, Jaggar JH. Carbon monoxide as an endogenous vascular modulator. Am J Physiol Heart Circ Physiol 2011; 301 (1): H1-H11.
23. Queiroga CS, Vercelli A, Vieira HL. Carbon monoxide and the CNS: challenges and achievements. Br J Pharmacol 2014; in press, doi: 10.1111/bph.12729.
24. Gupta A, Lacoste B, Pistel PJ, et al. Neurotherapeutic effects of novel HO-1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease. J Neurochem 2014; 131 (6): 778-90.
25. Nielsen VG, Arkebauer MR, Vosseller K. Redox-based thrombelastographic method to detect carboxyhemefibrinogen mediated hypercoagulability. Blood Coagul Fibrinolysis 2011; 22 (8): 657-61.
26. Nielsen VG, Pretorius E. Iron enhanced coagulation is attenuated by chelation: a thrombelastographic and ultrastructural analysis. Blood Coagul Fibrinolysis, 2014; 25 (8): 845-50.
27. Matika RW, Nielsen VG, Steinbrenner EB, Sussman AN, Madhrira M. Hemodialysis patients have plasmatic hypercoagulability and decreased fibrinolytic vulnerability: role of carbon monoxide. ASAIO J 2014; 60 (6): 716-21.
28. Thompson III JL, Nielsen VG, Castro A, Chen A. Heme oxygenase derived carbon monoxide and iron mediated plasmatic hypercoagulability in a patient with calcific mitral valve disease. J Thromb Thrombolysis 2014, in press, DOI 10.1007/s11239-014-1134-x.
29. Pretorius E. Quantifying changes in fibrin fiber network morphology. Ultrastruct Pathol 2011; 35 (4): 150-4.
30. Pretorius E, Steyn H, Engelbrecht M, Swanepoel AC, Oberholzer HM. Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients. Blood Coagul Fibrinolysis 2011; 22 (8): 696-700.
31. Kirino Y, Takeno M, Iwasaki M, et al. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther 2005; 7 (3): R616-24.
32. Le Blanc S, Villarroel P, Candia V, et al. Type 2 diabetic patients and their offspring show altered parameters of iron status, oxidative stress and genes related to mitochondrial activity. Biometals 2012; 25 (4): 725-35.
33. Nielsen VG, Galvani CA, Boyle PK, Steinbrenner EB, Matika RW. Bariatric patients have plasmatic hypercoagulability and systemic upregulation of hemeoxygenase-1 activity. Blood Coagul Fibrinolysis 2015, in press, PMID: 25101516.
34. Nielsen VG, Matika RW, Ley MLB, et al. Tissue type plasminogen activator induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer. Blood Coagul Fibrinolysis 2014; 25 (3): 248-53.